Intra-fractional target deviations ≤1 mm occurred in 95% of sessions, while target realignment in ≥2 mm deviations enabled treatment completion as scheduled. Nadir PSA at median 54 months follow-up was 0.19 ng/mL, and bRFS was 100%, 92.4% and 71.4% in low-, intermediate- and high-risk categories, respectively. Late Grade 2 GU and GI toxicities were 2.9% and 2.4%, respectively. No adverse changes in patient-reported quality of life scores were observed. CONCLUSION The unique spatial configuration of this prostate motion mitigation protocol enabled precise treatment planning and delivery that optimized outcomes of ultra-high 5 × 9 Gy hypofractionated radiotherapy of organ-confined prostate cancer. PURPOSE Sarcopenia is associated with adverse outcomes in several gastrointestinal malignancies and liver cirrhosis. We aimed to study the utility of magnetic resonance imaging (MRI) derived fat-free muscle area (FFMA) to predict clinical outcome in patients receiving yttrium-90 radioembolization (RE) for treatment of hepatocellular carcinoma (HCC). METHODS Fifty-eight patients with unresectable HCC and pre-interventional liver MRI undergoing salvage RE were retrospectively evaluated. Using axial T2-weighted turbo spin echo sequences, FFMA was calculated by subtraction of the intramuscular adipose tissue area from the total cross-sectional area of paraspinal skeletal muscles at the superior mesenteric artery level. FFMA values lower than 3582 mm2 in male and 2301 mm2 in female patients were defined as low FFMA. Main outcomes were progression-free survival (PFS) and overall survival (OS). For outcome analysis, the Kaplan-Meier method with log rank test and multivariate cox regression analysis were used. RESULTS Mean time from pre-interventional MRI to RE was 27 ± 20 days. Median OS and PFS after RE were 250 (range 21-1230 days) and 156 days (range 21-674 days), respectively. Patients with low FFMA showed significantly reduced OS (197 vs. 294 days, P = 0.024) and tended to have shortened PFS (109 vs. 185 days, P = 0.068). Low FFMA (HR 2.675; P = 0.011), estimated liver tumor burden (HR 4.058; P = 0.001), and Eastern Cooperative Oncology Group (ECOG) performance status (1.763; P = 0.009) were independent predictors of OS on multivariate analysis. CONCLUSIONS FFMA as a measure of sarcopenia predicts OS and might represent a promising new biomarker for survival prognosis in patients undergoing RE for treatment of unresectable HCC. PURPOSE South Asian (SA) have been observed to have higher cardiovascular mortality rates compared to East Asians (EA) and Caucasians.  https://www.selleckchem.com/products/jnj-64619178.html  Pericoronary adipose tissue (PCAT) attenuation around the right coronary artery (RCA) from coronary CT angiography (CTA) has been associated with coronary inflammation and cardiac death. We aimed to investigate i) the relationship between plaque characteristics and PCAT attenuation and ii) to assess gender and ethnic differences in PCAT attenuation using a matched cohort of SA, EA and Caucasians. METHOD Three-hundred symptomatic patients who underwent CTA were matched for age, gender, BMI and diabetes (100 in each ethnic group). Semi-automated software was used to quantify the total volumes and burden of non-calcified plaque (NCP), low-density non-calcified plaque (LD-NCP) and calcified plaque (CP) in blinded core-lab analysis. PCAT CT attenuation was measured around the RCA (10-50 mm from RCA ostium), the most standardized model for PCAT analysis. RESULTS The total volumes and burden of NCP, LD-NCP and CP were comparable in the ethnic groups (each p > 0.05). PCAT attenuation was higher in patients with coronary plaque. PCAT attenuation correlated with the total volumes and burden of NCP, LD-NCP and CP (r>0.17; p 0.39;p less then 0.001). Males showed higher PCAT attenuation (p less then 0.001). PCAT attenuation was similar between Caucasian, EA and SA (p = 0.32). CONCLUSIONS PCAT CT attenuation correlated most with its surrounded NCP features further highlighting its role as surrogate measure of coronary inflammation. As coronary plaque burden and RCA PCAT attenuation did not differ between ethnic groups, causes of increased cardiac mortality in South Asians needs further investigations. V.PURPOSE The type of pituitary adenoma (PA) cannot be clearly recognized with preoperative magnetic resonance imaging (MRI) but can be classified with immunohistochemical staining after surgery. In this study, a model to precisely immunohistochemically classify the PA subtypes by radiomic features based on preoperative MR images was developed. METHODS Two hundred thirty-five pathologically diagnosed PAs, including t-box pituitary transcription factor (Tpit) family tumors (n = 55), pituitary transcription factor 1 (Pit-1) family tumors (n = 110), and steroidogenic factor 1 (SF-1) family tumors (n = 70), were retrospectively studied. T1-weighted, T2-weighted and contrast-enhanced T1-weighted images were obtained from all patients. Through imaging acquisition, feature extraction and radiomic data processing, 18 radiomic features were used to train support vector machine (SVM), k-nearest neighbors (KNN) and Naïve Bayes (NBs) models. Ten-fold cross-validation was applied to evaluate the performance of these models. RESULTS The SVM model showed high performance (balanced accuracy 0.89, AUC 0.9549) whereas the KNN (balanced accuracy 0.83, AUC 0.9266) and NBs (balanced accuracy 0.80, AUC 0.9324) models displayed low performance based on the T2-weighted images. The performance of the T2-weighted images was better than that of the other two MR sequences. Additionally, significant sensitivity (P = 0.031) and specificity (P = 0.012) differences were observed when classifying the PA subtypes by T2-weighted images. CONCLUSIONS The SVM model was superior to the KNN and NBs models and can potentially precisely immunohistochemically classify PA subtypes with an MR-based radiomic analysis. The developed model exhibited good performance using T2-weighted images and might offer potential guidance to neurosurgeons in clinical decision-making before surgery. We designed and synthesized a novel series of piperidine propionamide derivatives as potent sigma-1 (σ1) receptor antagonists and mu (μ) opioid receptor agonists, and measured their affinity for σ1 and μ receptors in vitro through binding assays. The basic scaffold of the new compounds contained a 4-substituted piperidine ring and N-aryl propionamide. Compound 44, N-(2-(4-(4-fluorobenzyl) piperidin-1-yl) ethyl)-N-(4-methoxy-phenyl) propionamide, showed the highest affinity for σ1 receptor (Ki σ1 = 1.86 nM) and μ receptor (Ki μ = 2.1 nM). It exhibited potent analgesic activity in the formalin test (ED50 = 15.1 ± 1.67 mg/kg) and had equivalent analgesic effects to S1RA (σ1 antagonist) in a CCI model. Therefore, Compound 44, which has mixed σ1/μ receptor profiles, may be a potential candidate for treating neuropathic pain.